Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Salivary phenytoin radioimmunoassay

Salivary phenytoin radioimmunoassay 228 11 11 1 1 J. W. Paxton F. J. Rowell J. G. Ratcliffe D. G. Lambie R. Nanda I. D. Melville R. H. Johnson Departments of Materia Medica and Chemistry University of Glasgow and Radioimmunoassay Unit, Stobhill Hospital Scotland Institute of Neurological Sciences, Southern General Hospital University Department of Neurology Glasgow Scotland Summary A simple, specific and rapid radioimmunoassay (RIA) method for the assessment of nonprotein bound (‘free’) phenytoin (DPH) concentrations in mixed saliva is described. Epileptic patients on maintenance phenytoin therapy have mixed saliva phenytoin concentrations similar to ‘free’ drug levels measured directly in serum or cerebrospinal fluid (CSF). Salivary phenytoin levels are approximately 10% of the total serum level in treated epileptic patients and in normal subjects after ingestion of a single oral dose. The half time of disappearance of phenytoin after 100 or 300 mg doses is 12.2±3.0 (SD) h in serum and 12.3±3.2 (SD) h in saliva. This method of assessing the biologically active fraction of the drug may be particularly valuable in situations where serum protein binding is abnormal or in drug interactions. It is also non-invasive and requires small sample volumes (20µl) and may therefore be valuable in paediatric practice and in pharmacokinetic studies in which multiple venepunctures would otherwise be required. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Pharmacology Springer Journals

Salivary phenytoin radioimmunoassay

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/salivary-phenytoin-radioimmunoassay-utkpUM3PU8

References (20)

Publisher
Springer Journals
Copyright
Copyright © 1977 by Springer-Verlag
Subject
Biomedicine; Pharmacology/Toxicology
ISSN
0031-6970
eISSN
1432-1041
DOI
10.1007/BF00561791
Publisher site
See Article on Publisher Site

Abstract

228 11 11 1 1 J. W. Paxton F. J. Rowell J. G. Ratcliffe D. G. Lambie R. Nanda I. D. Melville R. H. Johnson Departments of Materia Medica and Chemistry University of Glasgow and Radioimmunoassay Unit, Stobhill Hospital Scotland Institute of Neurological Sciences, Southern General Hospital University Department of Neurology Glasgow Scotland Summary A simple, specific and rapid radioimmunoassay (RIA) method for the assessment of nonprotein bound (‘free’) phenytoin (DPH) concentrations in mixed saliva is described. Epileptic patients on maintenance phenytoin therapy have mixed saliva phenytoin concentrations similar to ‘free’ drug levels measured directly in serum or cerebrospinal fluid (CSF). Salivary phenytoin levels are approximately 10% of the total serum level in treated epileptic patients and in normal subjects after ingestion of a single oral dose. The half time of disappearance of phenytoin after 100 or 300 mg doses is 12.2±3.0 (SD) h in serum and 12.3±3.2 (SD) h in saliva. This method of assessing the biologically active fraction of the drug may be particularly valuable in situations where serum protein binding is abnormal or in drug interactions. It is also non-invasive and requires small sample volumes (20µl) and may therefore be valuable in paediatric practice and in pharmacokinetic studies in which multiple venepunctures would otherwise be required.

Journal

European Journal of Clinical Pharmacology – Springer Journals

Published: Jan 1, 1977

There are no references for this article.